Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
vancomycin + mitomycin C
- Development stage
- Preclinical
- Lead developer
- Aarhus University
- Modality
- Small Molecules, Peptides
- Administration
- Intravenous, Oral
01
Overview
Vancomycin + mitomycin C refers to either the combination of the glycopeptide antibiotic vancomycin and the alkylating antitumor antibiotic mitomycin C, or their covalent conjugate (VM). In preclinical research, the co-administration of vancomycin and mitomycin C has been evaluated in vitro against *Clostridioides difficile* infections, demonstrating additive but not synergistic activity. Additionally, researchers at Aarhus University have developed a vancomycin-mitomycin C conjugate (VM) linked via a disulfide bond. This conjugate acts as a targeted prodrug, where mitomycin C is selectively released at the bacterial cell surface by thiol-disulfide exchange triggered by bacterial cell surface thiols or reducing agents like N-acetylcysteine. The VM conjugate has demonstrated broad-spectrum antimicrobial activity against Gram-positive and Gram-negative bacteria, including vancomycin-resistant strains and *Staphylococcus aureus* biofilms, with reduced systemic cytotoxicity compared to free mitomycin C.
- Other names
- vancomycin-mitomycin C conjugatevancomycin/mitomycin C conjugateVM conjugate
02
Targets
DNADNA (Mammalian Deoxyribonucleic Acid)D-Ala-D-Ala (D-Ala-D-Ala terminus)
Beyond the preview
Go deeper on vancomycin + mitomycin C.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on vancomycin + mitomycin C.